公开(公告)号：US20220323405A1

公开(公告)日：2022-10-13

申请号：US17692094

申请日：2022-03-10

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/36 ,  A61P9/12 ,  A61K31/403

Abstract: A composition for treating an individual while reducing acute adverse effects of an empathogen/entactogen, including effective amounts of the empathogen/entactogen and an adverse effect-reducing agent that blocks adverse effects of the empathogen/entactogen. A method of treating an individual with an empathogen/entactogen and reducing its acute adverse effects, by administering an empathogen/entactogen to the individual, administering an adverse effect-reducing agent to the individual, and reducing the acute adverse effects of the empathogen/entactogen. A method of stopping the acute cardiostimulant and hyperthermic action of an empathogen/entactogen in an individual, by administering an adverse effect-reducing agent to the individual after the individual has taken the empathogen/entactogen and stopping the acute adverse effects of the empathogen/entactogen. A method of treating an individual at risk of cardiovascular events and/or hyperthermia with an empathogen/entactogen.

公开(公告)号：US20220096429A1

公开(公告)日：2022-03-31

申请号：US17549807

申请日：2021-12-13

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI

IPC: A61K31/36 ,  A61P25/22 ,  A61K31/48

Abstract: A method of enhancing positive therapeutic effects of a psychedelic, by inducing a positive psychological state in an individual with an empathogen/entactogen of MDMA administered in a dose of 20-200 mg, administering a psychedelic to the individual, and enhancing a positive response to the psychedelic. A composition including an entactogen/empathogen and a psychedelic in the same dosage form.

公开(公告)号：US20210386704A1

公开(公告)日：2021-12-16

申请号：US17230588

申请日：2021-04-14

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Patrick Raphael VIZELI

IPC: A61K31/36 ,  G16H10/20 ,  G16H20/10 ,  G16H70/40 ,  G16H10/60

Abstract: A method of dosing an empathogen/entactogen in treating patients, by assessing patient characteristics before empathogen/entactogen use, administering empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of determining a dose of an empathogen/entactogen based on body weight, sex, and CYP2D6 activity by assessing patient characteristics of body weight, sex, and CYP2D6 activity before empathogen/entactogen use, administering the empathogen/entactogen to the patient based on the patient characteristics, and producing maximum positive subjective acute effects in the patient. A method of refining dosing of an empathogen/entactogen. A method of predicting future dosing with an empathogen/entactogen. A method of evaluating feasibility of patients to receive an empathogen/entactogen as treatment. A method of optimizing empathogen/entactogen treatment in a patient.

公开(公告)号：US20210315884A1

公开(公告)日：2021-10-14

申请号：US17225715

申请日：2021-04-08

Applicant: Universitätsspital Basel

Inventor： Matthias Emanuel LIECHTI ,  Friederike Sophie HOLZE

IPC: A61K31/48 ,  A61K31/4045 ,  A61K31/675 ,  A61K31/137 ,  A61P25/24 ,  G01N33/68

Abstract: A method of dosing and treating patients with a psychedelic, by administering a psychedelic at a dose of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects. A method of determining a dose of a psychedelic for an individual, by administering a dose of a psychedelic to the individual of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, and adjusting the dose to provide more positive acute effects than negative acute effects in the individual. Methods of treating psychiatric conditions or providing therapy. A method of defining therapeutic doses of a psychedelic in clinical trials. A method of monitoring individuals for depression after treatment with LSD.